Compare SACH & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SACH | GRML |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | 27 | 5 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | SACH | GRML |
|---|---|---|
| Price | $1.02 | $0.29 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 646.0K | ★ 3.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.27 |
| 52 Week High | $1.45 | $0.55 |
| Indicator | SACH | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 32.24 |
| Support Level | $0.99 | $0.27 |
| Resistance Level | $1.13 | $0.44 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.45 | 14.94 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.